Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib.

ABSTRACT:

Introduction

Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR+ NSCLC treated with osimertinib.

Methods

This is a retrospective multicenter cohort study that included patients with metastatic EGFR+ NSCLC who were treated with osimertinib between February 2016 and September 2021. Demographics, bone metastases-related outcomes, SREs, treatment efficacy, and overall survival (OS) were collected.

Results

In total, 250 patients treated with osimertinib (43% first line) were included. Of the patients, 51% had bone

SUBMITTER: Brouns AJWM 

PROVIDER: S-EPMC10165134 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature